Catalyst Capital Advisors LLC Sells 4,825 Shares of Novartis AG $NVS

Catalyst Capital Advisors LLC reduced its holdings in shares of Novartis AG (NYSE:NVS) by 10.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,817 shares of the company’s stock after selling 4,825 shares during the period. Catalyst Capital Advisors LLC’s holdings in Novartis were worth $6,540,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Angeles Wealth Management LLC increased its stake in Novartis by 33.9% in the first quarter. Angeles Wealth Management LLC now owns 4,286 shares of the company’s stock valued at $655,000 after purchasing an additional 1,086 shares in the last quarter. Bessemer Group Inc. grew its position in Novartis by 46.1% in the 1st quarter. Bessemer Group Inc. now owns 59,061 shares of the company’s stock valued at $9,022,000 after purchasing an additional 18,649 shares during the period. Avalon Trust Co grew its holdings in shares of Novartis by 9.7% during the first quarter. Avalon Trust Co now owns 1,500 shares of the company’s stock valued at $229,000 after buying an additional 133 shares during the last quarter. Gerald Baker Financial Group LLC bought a new position in Novartis in the 1st quarter valued at about $335,000. Finally, SteelPeak Wealth LLC acquired a new position in Novartis during the 1st quarter valued at about $276,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Price Performance

Shares of NYSE NVS opened at $153.78 on Friday. The stock has a market cap of $293.44 billion, a PE ratio of 22.03, a price-to-earnings-growth ratio of 2.63 and a beta of 0.45. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85. The stock has a fifty day moving average of $151.41 and a 200-day moving average of $151.61.

Novartis (NYSE:NVS) last posted its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. During the same period last year, the company posted $2.28 EPS. The business’s revenue was down .9% on a year-over-year basis. Equities research analysts anticipate that Novartis AG will post 8.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley increased their target price on shares of Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.